Partner Dan Shores will present at the Intellectual Property Owners Association (IPO) Pharmaceutical & Biotechnology Issues Committee Meeting on Thursday, February 2, 2023 on the mRNA/LNP IP Landscape.
The Pharma & Biotech Issues Committee advises the IPO Board of Directors regarding global legislative changes, patent office policies, regulatory issues, and judicial decisions affecting the pharmaceutical and biotechnology industry. This includes pharmaceuticals subject to the Drug Price Competition and Patent Term Restoration Act (the Hatch-Waxman Act), the Biologics Price Competition and Innovation Act (the BPCIA Act), and international counterpart laws and regulations. The Committee’s primary goal is to review proposed legislative and regulatory initiatives, and proactively submit comments and recommendations to the Board that reflect the proper balance between generic drug/biosimilar entry and maintaining strong incentives for the discovery, development, and protection of new pharmaceutical products, on a global basis. A secondary goal of the committee is to monitor and comment upon global judicial decisions and proposed patent practice changes in consultation with other IPO committees for the education and benefit of IPO members.
To learn more about the IPO and the Pharma & Biotech Issues Committee, please visit the IPO website.
